Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05286203 · ClinicalTrials.gov registry record · NA

Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing

A NA study of Uveitis and Infectious Disease, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT05286203: Recruiting NA study of Uveitis and Infectious Disease, sponsored by University of California, San Francisco.

NCT05286203 is a NA study of Uveitis and Infectious Disease that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 100 participants, below the 612-participant average among 19 other Uveitis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05286203, a NA study of Uveitis and Infectious Disease, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This is a multi-center randomized controlled evaluator-masked trial designed to compare metagenomic deep sequencing (MDS) versus standard of care testing for improvement of outcomes for intraocular infections. Patients with presumed intraocular infections who meet the eligibility criteria will be randomized to receive MDS testing results or not to receive MDS testing results. All patients will receive standard-of-care testing to guide management. Enrolled patients will be followed at week 2, week 3-6 (randomization visit), and at 4 weeks after the randomization visit. The proportions of patients who received the appropriate therapy and the proportions of patients with improved outcome will be compared between arms. Patient quality of life, MDS performance, and the provider certainly of belief will be collected.

Primary Outcome

Dichotomous variable (Y/N) as assessed by a masked evaluator

Interventions

  • DEVICE Metagenomic Deep Sequencing (MDS)
  • DIAGNOSTIC_TEST Standard of Care (SOC)

Study Locations (1)

California

  • University of California San Francisco (UCSF) - San Francisco

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-06-06
Est. Completion 2026-12
Phase NA

What NCT05286203 shows while recruiting

NCT05286203 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 612-participant average among 19 other Uveitis trials with a reported enrollment target (84% lower).

The record links to 2 conditions, with Uveitis appearing as the primary indexed condition, and to 2 interventions - of which Metagenomic Deep Sequencing (MDS) is the first listed.

NCT05286203 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05286203 about?

NCT05286203 is a clinical study titled "Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing". This is a multi-center randomized controlled evaluator-masked trial designed to compare metagenomic deep sequencing (MDS) versus standard of care testing for improvement of outcomes for intraocular infections. Patients with presumed intraocular infections who meet the eligibility criteria will be ra...

What is the current status of trial NCT05286203?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-06-06. Estimated completion is 2026-12.

What conditions does trial NCT05286203 study?

This clinical trial studies the following conditions: Uveitis, Infectious Disease.

What interventions are being tested in trial NCT05286203?

The interventions under investigation include: Metagenomic Deep Sequencing (MDS) (DEVICE), Standard of Care (SOC) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05286203?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05286203 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uveitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05286203's enrollment target sits among peer trials

100 11th of 19 higher than 7 of 19 other Uveitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Uveitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05286203, the US trial registry maintained by the National Library of Medicine. NCT05286203 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.